(Oslo ,24 January 2020 ) Exercise of employee share options In connection with the expiry date at 24 January three employees inNavamedic ASA have exercised a total of 275,000 options inObserve Medical ASA . Employees inNavamedic ASA were granted options inObserve Medical ASA in connection with the demerger ofNavamedic ASA's Medtech division with transfer toObserve Medical ASA 31 October 2019 . The weighted average option exercise price isNOK 3.12 . Shares issued upon exercise are subject to a lock-up period of 12 months after exercise. Increased share capital Following the share option exercise the Board of Directors, pursuant to authorization granted byObserve Medical ASA's General Meeting on1 October 2019 , has decided to increase the Company's share capital byNOK 71,500 by issuing 275,000 new shares, of par valueNOK 0.26 . Following the increase,Observe Medical ASA's share capital isNOK 3,989,094.98 divided into 15,342,673 shares. Mandatory notification of trade Options exercised by primary insiders23 January 2020 :Kathrine Gamborg Andreassen has exercised 125,000 options in the Company, corresponding to 125,000 shares at the strike price ofNOK 3.12 . After exercising options,Kathrine Gamborg Andreassen holds 125,000 options and 541,668 shares in the Company. For further details, reference is made to the prospectus issued byObserve Medical ASA on1 November 2019 , which is available on the company's web site www.observemedical.com. For further information, please contact:Björn Larsson , CEO ofObserve Medical Mobile: +46 76 620 17 25 E-mail: bjorn.larsson@observemedical.com AboutObserve Medical ASA :Observe Medical develops and markets innovative hospital products that contribute to increased patient safety and a more efficient care system. The Company's headquarter is inOslo and its operations are based out ofSweden .Observe Medical's initial product was Sippi®, the only digital urine meter with wireless data transfer to patient data management systems, which also prevents bacterial migration that can lead to urinary infections (Sippcoat®). Sippi® is CE marked and is currently being launched at selected hospitals in the Nordics andGermany .
Click here for more information
© Oslo Bors ASA, source